Symposium booklet 2016

Proffesional Services In All Spheres Of Healthcare
M. P. SHAH HOSPITAL
20 2016
SESSION I
PAEDIATRIC
INFECTIONS
SESSION II
FUNGAL
INFECTIONS
SESSION III
BACTERIAL
INFECTIONS
SESSION IV
HAEMORRHAGIC
VIRAL FEVERS
SESSION V
NEGLECTED
INFECTIONS

Professional Services In All Spheres Of Healthcare2
M.P. SHAH HOSPITAL UPDATE
M.P. Shah Hospital is a Social Service league Hospital which has been in existence for the last 83 years, as
a ‘not for profit’ organization. The Hospital has one single social objective of providing quality, affordable
health care services to the community at affordable costs. It is a multi-super-specialty, state-of-the art,
tertiary care hospital with a current capacity of 210 fully operational beds, 30 dedicated critical care
beds, 10 renal dialysis units and 12 chemotherapy units. It provides all the modern out-patient and in-
patient facilities with dedicated pavilions/ wards, specialty clinics, advanced radiology, pathology and
Cath lab operations. We are going through exciting times of development and redefining the way health
care is delivered in East and Central Africa region.

Professional Services In All Spheres Of Healthcare 3
CONTENTS
Symposium Schedule
Message from the Chairman
Message form the CEO
Message From the Symposium Chairman
Speakers Profiles
Panelists Profiles
Hospital Update
Sponsors Acknowledgement
Notes
Symposium Committee Members
04 - 05
06
07
08
09 - 15
16 - 20
21 - 32
33 - 40
41- 42
43

SESSION TIME TOPIC SPEAKER CHAIRS
SCHEDULESESSIONI(Pfizer)
07 30
07 40
08 00
08 20
08 40
09 30
09 50
10 10
10 30
10 50
11 30
11 50
12 10
12 30
12 50
13 10
13 40
09 00
11 20
Opening Ceremony
Update on TB diagnostics
New paradigm in the treatment of tuberculosis
Invasive candidiasis
Aspergillosis
Intersession Break / Q & A
Chairman of The M.P. Shah Hospital
Recent advances in management of
H-pylori disease in children
Hepatitis C - (Are we nearing cure)
IPC programme at M.P. Shah Hospital
TEA BREAK
Emerging trends in hospital infections
Science behind antibiograms & antibiotic guidelines
Molecular epidemiology of MRSA
How would I manage multi - resistance gram
negative organisms - New Horizons
Use of Immunodulators in Sepsis and Severe Sepsis
LUNCH BREAK
Dr. S Patel
Dr. C Mwachari
Dr. M Chakaya
Dr. E Oundo
Prof. R Adam
Dr. M Shah
Dr. A Laving
Dr. R Shah
CNI F Kamau
Dr. D Silverstein
Dr. L Achieng’
Dr. G Omuse
Dr. E Omonge
Dr. R Jaju
Prof. R Adam
&
Dr. S Dhirane
Prof. G Revathi
&
Dr. H Saha
SESSIONII(MSD)SESSIONIII(AstraZeneca)
Prof. G Lule
&
Dr. B Samia

SESSION TIME TOPIC SPEAKER CHAIRS
SCHEDULE
Each session is worth 5 CPD points
14 10
14 30
14 50
15 10
15 30
16 00
16 30
16 50
16 10
17 10
17 30
18 00
Prof. G Revathi
Dr. J Wachira
Dr. A Agweyu
Dr. R Virani
Dr. S Mauro
Prof. O Anzala
Prof K Bhatt
Dr. C Abeid
Mr. A Das
Dr. M Lumba
&
Dr. J Mbuthia
SESSIONV(Getz)
PediatricUTIandimplicationsforantimicrobial
stewardship
New Born Sepsis - What is new
Management of pneumonia - WHO classification
and treatment
Prevention of pneumococcal diseases and the
role of currently available vaccines.
Afternoon Tea Break
Synopsis of arbo virus infections in Kenya with
special interest to chickungunya and dengue virus.
Update on Zika VIrus
Update on Kala Azar
Clinical continuum Chronic kidney disease and
infectious diseases
CEO’s vote of thanks
SESSIONIV(Glaxo)
Dr. J Aluoch
&
Dr. A Shah

Dr. Manoj Shah
FROM THE CHAIRMAN I M.P. Shah Hospital
Dear Participants,
On behalf of the M.P. Shah Hospital we wish to warmly Welcome you to the M. P. Shah Hospital 5th Annual
Symposium. This is a great opportunity for us to host you, as you attend, participate and network at this
symposium. I wish to sincerely thank and appreciate, Dr. S.T. Patel for his leadership and vision for making this
symposium truly international.
Previous symposiums have seen many hospitals positively impact the community with information that has
helped improve healthcare practices throughout the country. We note with concern that infectious disease
are still a major healthcare burden in the developing world. Evolving resistance and a profound lack of new
antibiotics further compound the situation. These concerns were the driving force behind the introduction
of the M. P. Shah Hospital INFECTIOUS DISEASES Symposium, a forum that would begin to address the
aforementioned challenges and increase awareness on current best practice, trends and technologies.
Over eighty years have passed since M. P. Shah Hospital began as a simple nursing home to provide quality,
affordable healthcare services to the community. We have since grown into a fully-fledged hospital providing
a variety of health services. This high level of service has been our hallmark for the past eight decades, and
has remained consistent as we touch lives and bring hope to many in the region.
The past few years have seen significant progress for the Hospital, both in terms of its physical infrastructure
as well as its systems and processes. These changes have continued to align the hospital as a center of
excellence for quality healthcare in the region.
A key development is the commencement of complete Paediatric services in the newly built state-of-the-
art Suryakala Maganlal Chandaria Children’s Medical Center. This brand new children’s hospital is a 5 storey
center offering both Outpatient and Inpatient Paediatric services including Neonatal and Paediatric ICU as
well as private rooms for children separated by age category. A resident team of Paediatrically-trained doctors
and nurses run the service, including a Paediatric Intensivist.
In addition, the hospital has completed an additional 5 storey tower as part of its long-term development.
The Dr. Kanubhai Babla Medical Center, houses our brand new ICU, Theatre, Cardiac Diagnostic Center and
Cath Lab, along with executive private patient rooms.
The Hospital is going through an exciting phase of development and it has launched a brand new Cardiac
Center focused towards improving lifestyle diseases related to heart like hypertension, stroke, angina,
hyperlipidemia, diabetes etc. The Dr. Rasik Kantaria Cardiac Center is located on the 5th floor of the Dr.
Kanubhai Babla Medical Center. It is a world-class medical center offering the complete range of advanced
cardiac diagnostics and medical treatment options for adults and children with heart related diseases. This
Cardiac Center is managed by world class doctors and a team of expert technicians and trained nurses.
With all these developments as well as those in the pipeline, the Hospital is poised to take its place as a center
of excellence for outstanding healthcare in the region.
For this remarkable service I extend the leadership’s most sincere gratitude and appreciation to you all. This
success would not be possible without your support over the years. M. P. Shah Hospital stands tall on your
shoulders.
I wish you good deliberations at this symposium.

Mr. Anup Das
FROM THE C.E.O. I M.P. Shah Hospital
On behalf of the Board, Management and Organizing Committee, of The Social Service League, M.P.Shah
Hospital, I am delighted to welcome all the Distinguished Speakers, Corporate sponsors , Exhibitors,
Stakeholders and Delegates to the M.P. Shah Hospital’s 5th infectious diseases symposium. This is one of
the Hospital’s largest annual events which has gained prominence with every passing year with its particular
objective in providing a successful forum for researchers and clinicians from all over the region, to showcase
very informative and interesting case studies as well as exchange ideas on Infectious Diseases, with the goal
of providing the best possible care for our patients and communities. This symposium will give participants a
platform to discover novel opportunities, meet with colleagues, and broaden their knowledge.
I also welcome you to come and see the new infrastructure of M.P. Shah Hospital and witness the change in
providing world class healthcare, infrastructure and services. Please visit the following new developments in
this hospital:-
• New State of the art Children’s hospital with its own 24 hours casualty, Well-baby center, Sub Specialty
clinics, NICU, PICU & PHDU.
• New State of the art, most modern Intensive Care Unit and High Dependency Unit set up in the
region, at the ground floor of Dr. Kanubhai Babla Medical Center.
• New cardiac center with specialized cardiac diagnostics and state of the art Cath Lab doing all kinds
of interventional cardiac procedures.
• New executive and private rooms at the 2nd and 3rd floor of Dr. Kanubhai Babla Medical Center.
• New Laminar floor theatre at the 1st floor of Dr. Kanubhai Babla Medical Center.
• New 3 Tesla MRI, 128 Slice Cardiac CT Scan, digital X Ray, Mammography, 4D Ultrasounds and OPG
units in the radiology center.
• Automated hematology analyzer, New fully automated Biochemistry equipment, Fully Automated
microbiology unit & automated Histopathology units in the Pathology Lab. Our laboratory is able to
perform more than 5000 different kinds of tests.
• Brand new dental center with maxillofacial and orthodontic specialties.
• Brand new ENT center with all modern equipment, possibly the best in East and Central Africa region
and Audiology Unit.
• A modern wound management clinic and trauma center at the Accident and Emergency unit.
• Renal center with advanced Dialysis units, CRRT machines and Kidney transplant unit.
• We are doing all kind of Orthopedic implants, replacement surgeries, Neuro & Spine procedures
• Our Maternity center gives birth to on average 150 babies every month and it is growing every day.
• Our Accident & Emergency unit receives around 6000 patients every month and is improving every
day.
• We have state of the art oncology management unit with Chemotherapy, Oncology surgeries, in
patient management & Palliative care.
I look forward to your participation in the sessions and I encourage you to take advantage of the wealth
of knowledge offered by our speakers and participate in the interactive sessions, as we strive to grow by
building a cohesive, cooperative healthcare system.

FROM THE CHAIRMAN I Infectious Disease Symposium
Dr. S. Patel
Once again it’s August and it’s time for the 5th infectious diseases symposium, and On behalf of the Organizing
Committee, I would like to warmly welcome you all to the M.P. Shah Hospital’s 5th infectious diseases
symposium.
Sub-Saharan Africa has borne the major brunt of infectious disease, including HIV-AIDS, Ebola and now Zika is
with us. Keeping up with this theme we now have the 5th edition of the Infectious Diseases Symposium. This
symposium is one of the Hospital’s largest annual events and it serves as a forum to facilitate interdisciplinary
scientific discussions on various aspects of infectious diseases management. It is recognized by the Medical
Practitioners & Dentist Board for CME accreditation and we are confident that it shall provide a unique
Educational experience, through the distinguished presenters. They will focus on the impact of change on
clinical and laboratory aspects of infectious diseases as well as the current burden of infectious diseases in
global public health as well as the changing pathogenic landscape due to emerging and re-emerging infections.
These sessions will also cover current challenges and future trends in infectious disease diagnostics.
Thesymposiumwillprovideyouwithauniqueopportunitytolearnabouttheglobaltrendsandmostsignificant
developments in infectious diseases, as well as to network with a vast group of diagnostics experts, clinicians
and opinion leaders. This year we expect over 500 Senior Medical Professionals to attend the symposium.
Today is a result of months of planning by the dynamic, young, organizing committee who have seen this
event through to the end while adding quality to every aspect.
Lastly the success of this Programme would not have been possible without the tireless work of the speakers
and chairpersons today. A special debt of gratitude goes to the Chairman of M.P. Shah Hospital Dr. Manoj
Shah and his board whose total support allows this symposium to go from strength to strength. Thanks to
the Hospital C.E.O Mr. Anup Das and his administration team for their moral support and effort in making
this event a success. We also thank all our sponsors without whose support this event would not have been
suuccessful.
We look forward to a very stimulating and engaging event. Any feedback for an improved symposium will be
well received.

SPEAKERS PROFILES & ABSTRACTS I Session I: Paediatric Infections
Dr. J Wachira
Senior Consultant Paediatrician - M.P Shah Hospital
Fellow of the Royal College of Paediatrics & Child Health-UK
M.Med Paediatrics & Child Health/MBChB- University of Nairobi
Executive Board member- Kenya Paediatrics Association- (KPA)
Ex- Temporary advisor World Health Organization (WHO) in neonatal and pediatrics
acute care management
Ambrose is a Kenyan paediatrician with Masters training in epidemiology, based at the
KEMRI-Wellcome Trust Research Programme in Nairobi. Working closely with the Kenya
Ministry of Health in 2009, his early research involved conducting systematic reviews for
a national exercise to adapt the World Health Organization paediatric clinical practice
guidelines using the GRADE methodology. Following this, Ambrose was invited to support
similarexercisesinUgandaandRwanda.Morerecently,hewastheprincipalinvestigatoron
a large pragmatic clinical trial comparing antibiotic treatments for childhood pneumonia.
The findings of this study contributed towards a recent major revision in the Kenyan
guidelines, and are likely to eventually influence practice in the region. As he approaches
the end of his PhD studies, he is currently considering future areas of work that build
on his interest in conducting pragmatic trials for interventions to improve the care and
outcomes of hospitalized children in sub-Saharan Africa.
Case Management of Childhood Pneumonia: Revised WHO and Kenya Ministry of Health Classifications and
Treatment
Childhood pneumonia claims over one million lives annually and is a leading cause of morbidity worldwide. The
case management guidelines for childhood pneumonia currently in use in Kenya and many other countries in
sub-Saharan Africa were developed by the World Health Organization (WHO) have been credited for contributing
towards substantial reductions in pneumonia deaths. There is however uncertainty over the effectiveness of
the guidelines in the current era against a background of the introduction of vaccines targeting Haemophilus
influenzae type B and Streptococcus pneumoniae - the leading causes of bacterial pneumonia in children. Results
from clinical trials conducted in predominantly Asian populations demonstrating clinical equivalence between
amoxicillin and benzyl penicillin led to a revision of the WHO pneumonia guidelines in 2013. However, Kenyan
policy makers declined to support a similar change in the local guidelines in the absence additional supportive
evidence from African populations citing concerns of high mortality in Africa.
Weconductedconductingamulti-centrepragmaticclinicaltrialtocomparetheeffectivenessofthetwoantibiotics.
A total of 527 children aged 2–59 months with severe pneumonia as defined in the 2005 WHO guidelines were
recruited from 6 public hospitals across Kenya. The risk of treatment failure was 7.7% in the amoxicillin arm and
8.0% in the benzyl penicillin arm at 48 hours in per-protocol analyses (risk difference, −0.3% [95% CI, −5.0% to
4.3%]), indicating non-inferiority within the pre-specified margin of 7% at 48 hours. Similar results were obtained
in intention-to-treat analyses. Mortality was low (0.8%) and comparable to reported findings of the previous
trials conducted in Asia that informed the WHO technical updates in 2013.
The findings of this study offer important evidence for policy makers in sub-Saharan African considering the local
adaptation of the recent global recommendations for the management of childhood pneumonia. This work has
been used to inform a 2014 national guideline panel meeting that revisited the Kenyan guidelines on treatment
of pneumonia. The panel reviewed the available evidence, including an updated systematic review that included
the Kenyan trial results. Draft recommendations to change policy based on this trial and other evidence were
presented to the Ministry of Health and accepted as new national treatment guidelines in early 2015.
New Born Sepsis
Dr. A Agweyu

SPEAKERS PROFILES & ABSTRACTS I Session I: Paediatric Infections
Dr. A Laving
Dr. A Laving is the Program Coordinator for undergraduate students, Department of
Paediatrics&ChildHealth,UniversityofNairobi.Responsibleformakingtheundergraduate
teaching program, from lecture schedule, tutorial topics to clinical teachings in the wards
as well as co-ordinating their ward, newborn unit and child health rotations.
Participate in teaching paediatric residents, medical and nursing students, supervising
research protocols of residents, development of undergraduate and postgraduate
programs and preparing examinations for the Department of Paediatrics and Child Health
at the University of Nairobi. Participate in running of the paediatric gastroenterology and
general paediatric services at Kenyatta National Hospital. Conduct major teaching ward
rounds, a general paediatric outpatient clinic and a paediatric gastroenterology/liver
clinic once a week, as well as weekly clinical bedside teaching sessions with fourth year
medical students and paediatric residents. Consulted for all paediatric GIT issues at the
national referral and teaching hospital. Perform diagnostic and therapeutic upper and
lower endoscopies and supervise percutaneous liver biopsies on children.
Dr. R. Shah
Dr. Reena Shah is the Interim Chair of the Department of Medicine, AKUHN. She is an
Assistant Professor of Medicine and Section Head for Infectious Diseases. Dr. Shah
completed her MBBS at the University of Southampton, UK and had been a member of
the Royal College of Physicians (MRCP) London since 2000. She obtained a Diploma in
Infectious Diseases from the University of London as well as a Diploma in Tropical Medicine
from the London School of Hygiene and Tropical Medicine. Following this she obtained a
Masters in Infectious Diseases from the University of London. She was awarded Fellowship
to the Royal College of Physicians Edinburgh FRCPE in 2014. Her clinical research interest
is primarily in the area of HIV/AIDS and hepatitis B. She is currently Chair of the Antibiotic
Sub-Committee of the Pharmacy and Therapeutics Committee and also the Vice-Chair of
the Kenya HIV Clinicians Association and member of the British HIV Association.
Dr. L Achieng’
Dr. L Achieng’ Is a Physician and Infectious Disease Specialist. She Is a Lecturer in
Internal Medicine at the University of Nairobi and an Adjunct Assistant Professor of
Medicine at the University of Texas Medical Branch. She heads the Infectious Diseases
Unit at the Kenyatta National Hospital and is a member of several Antibiotic stewardship
committees and the National Antimicrobial Stewardship Advisory Group.
Research interests include improving outcomes in sepsis, antimicrobial stewardship
and in cardiovascular disease in HIV
Antibiotics are among the most commonly prescribed medications and this has led to an increase in
development of drug resistance. Increasing resistance makes selection of appropriate empiric antibiotics
more challenging. As the global community grapples with the emergence of multi drug resistant organisms,
it is imperative that all health facilities develop appropriate antibiograms to guide the activities of antibiotic
stewardship committees. The onus remains on clinicians to prescribe antibiotics only when necessary and
for the shortest duration possible. In this session we will look at the science of antibiograms and how these
should guide our practice as clinicians
Recent advances in management of H-pylori disease in children

SPEAKERS PROFILES & ABSTRACTS I Session II: Fungal Infections
Dr. E Omonge
Dr. Omonge is qualified in MBChb (Nairobi) and MMed (Nairobi)
He is a leading authority in clinical therapeutics and pharmacology.
He has an interest in HIV medicine and a respected member of the faculty at the
University of Nairobi.
He is the general secretary of society of AIDS in Africa and the Kenya HIV Clinicians
Association
He has authored numerous research articles in the field of HIV and Diabetes.
Dr Enoch Omonge is a lecturer in the department of Clinical Medicine and therapeutics, thematic unit of
Clinical Pharmacology.
His special interest is HIV Medicine and Rational Antimicrobial use .
Has contributed to developing Antibiotherapy protocols and HIV care at the KNH.
Current research interest is HIV associated coinfections and comorbidities
Dr. G Omuse
Dr. Geoffrey Omuse is an Assistant Professor and Consultant Clinical Pathologist at the
Aga Khan University Hospital Nairobi. He has very diverse research interests including
several publications on infections due to Staphylococcus aureus in Kenya. In 2013 he
completed a month long training on molecular typing of Staphylococcus aureus as
part of a technology transfer grant at Tygerberg Hosital, Stellenbosch University, South
Africa.
Title: MRSA in Kenya-Filling the gap
Several studies looking at the prevalence of MRSA in Kenya have been published. However, there is a paucity
of knowledge on the molecular epidemiology of MRSA in Kenya and indeed East Africa. Understanding the
molecular epidemiology is necessary in order to better assess the relationship between circulating strains
and propensity to cause disease. This also helps when investigating MRSA outbreaks and in evaluating the
effectiveness of infection control measures put in place to prevent and control MRSA outbreaks.
Dr David Silverstein is a Consultant Cardiologist and an Internist at the Nairobi Hospital for
the last 30 years. He came to Kenya in 1974 as a lecturer and then senior lecturer in the
University of Nairobi and subsequently Chief Cardiothoracic physician for the government
of Kenya. He entered private practice in 1981 and has served on the Medical Advisory
Committee and was elected member of the Board for 17 years.
He got his MD degree for the University of Chicago and then went to the University of
Washington for his internal medicine residency and Cardiology fellowship. He is a Fellow of
the American College of Cardiology (FACC) and the American college of Physicians (FACP).Dr. D Silverstein
Imerging trends in hospital infections

SPEAKERS PROFILES & ABSTRACTS I Session II: Fungal Infections
Dr. E Oundo
Dr. Oundo graduated in 2013 from Moi University with M.B.Ch.B after which he joined
Tenwek Hospital in 2014 for internship. In 2015, he worked in casualty department in
Longisa County referral hospital in 2015. He then moved to MPSHAH hospital where he
currently works as a medical officer in HDU/ICU department. He has a deep interest in
internal medicine.
Problem; candidiasis is a common and important problem affecting critical care set ups in our facilities.
Cause: the most common species is C. albicans, but there are increasing isolation of C. glabrata, C. krusei and
C. parapsilosis. There are multiple risk factors, including an ICU patient, immunocompromised, neutropenia,
recent surgery, and central catheters. These factors also increase the risk of contracting fluconazole-resistant
strains.
Manifestation: infection is usually from GIT penetration, biofilms, localized focus, and colonization, which lead
tohematogenousspread.Itcanthenaffectmultipleorgansandorgansystems:osteoarticular,endophthalmitis,
periotonitis and abdominal infections, pneumonia and empyema, mediastinitis, hepatosplenic involvement,
and candidemia.
Diagnosis: the main diagnostic modalities are blood culture, biopsy, beta-D-glucan assay, PCR, colonization
index and candida score. Susceptibility testing is important for streamlining therapy, de-escalation and
following of resistance patterns.
Treatment mainly involves adequate source control and proper choice of antifungals. Antifungal choice will
depend on resitance patterns, culture results, and the underlying status of the patient. The arsenal is azoles,
echinocandins, and amphotericin B.
Mortality ranges from 30-60% depending on time of initiation of antifungals and severity of the infection.
Outcomes are worse with tumors, neutropenia and higher APACHE II scores.
Dr.
Oundo
Emmanuel
Owiti,

M.B.Ch.B,
2013,

MP
SHAH
Hospital
HDU/ICU
Medical
officer

Abstract

Problem;
candidiasis
is
a
common
and
important
problem
affecting
critical
care
set
ups
in
our
facilities.

Cause:
the
most
common
species
is
C.
albicans,
but
there
are
increasing
isolation
of
C.
glabrata,
C.
krusei

and
C.
parapsilosis.
There
are
multiple
risk
factors,
including
an
ICU
patient,
immunocompromised,

neutropenia,
recent
surgery,
and
central
catheters.
These
factors
also
increase
the
risk
of
contracting

fluconazole-‐resistant
strains.

Manifestation:
infection
is
usually
from
GIT
penetration,
biofilms,
localized
focus,
and
colonization,

which
lead
to
hematogenous
spread.
It
can
then
affect
multiple
organs
and
organ
systems:

osteoarticular,
endophthalmitis,
periotonitis
and
abdominal
infections,
pneumonia
and
empyema,

mediastinitis,
hepatosplenic
involvement,
and
candidemia.

Diagnosis:
the
main
diagnostic
modalities
are
blood
culture,
biopsy,
beta-‐D-‐glucan
assay,
PCR,

colonization
index
and
candida
score.
Susceptibility
testing
is
important
for
streamlining
therapy,
de-‐
escalation
and
following
of
resistance
patterns.

Treatment
mainly
involves
adequate
source
control
and
proper
choice
of
antifungals.
Antifungal
choice

will
depend
on
resitance
patterns,
culture
results,
and
the
underlying
status
of
the
patient.
The
arsenal

is
azoles,
echinocandins,
and
amphotericin
B.

Mortality
ranges
from
30-‐60%
depending
on
time
of
initiation
of
antifungals
and
severity
of
the

infection.
Outcomes
are
worse
with
tumors,
neutropenia
and
higher
APACHE
II
scores.

Festus Kamau is a Clinical Nurse Instructor, and a lead Diabetic Nurse at the M.P. Shah
Hospital. Has previously worked at the Aga Khan University Hospital and The Nairobi
Hospital.
He is trained in Critical Care and has interest in the Infection Control.
He got his training from the Kenya Medical Training College Nursing School.
He is a member of the Critical Care Nursing Chapter and Infection Control Nursing Chapter.
It is the discipline concerned with preventing healthcare-associated infections within a healthcare facility.
As such, it is a practical (rather than an academic) sub-discipline of epidemiology.
It is an essential (though often under-recognized and under-supported) part of the infrastructure of health
care.
Infection prevention and control is akin to public health practice, practiced within the confines of a particular
health-care delivery system rather than directed at society as a whole.
CNI F Kamau

SPEAKERS PROFILES & ABSTRACTS I Session IV: Haemorrhagic Viral Fevers
Dr. S Mauro
Prof. O Anzala
Dr. Mauro was born in Torino on 14th April, 1952. He Graduated in Medicine with honours at
the University of Torino in November, 1977. Post graduated in Tropical Medicine with honours
in Rome University. Came to Kenya in 1980 and worked for field experience at the Mathari
Consolata Missionary Hospital. He joined The Nairobi Hospital Medical team in 1982 and in
1985 joined Dr. Philip Rees in full private practice. Since then he has been working as a specialist
in the Tropical and Travel Medicine field. He is an author of many publications in several
internationally renowned journals and has been an invited speaker to International Congresses
in New York, Florence, Venice, Budapest and Canada. Malaria is his main interest. He has been
instrumental in bringing the Artemisinin derivative in Africa and the first one to use Artemether
in Kenya in 1999. He has been a member of Malaria Task Force and Malarone Project.
Prof.AnzalaistheTechnicalAdvisor,KenyaMedicalLaboratoryTechnicians&TechnologistsBoard.
Reviewer, East African Medical Journal.
ProjectManager,KenyaAIDSVaccineInitiative(KAVI),DepartmentofMedicalMicrobiology,
University of Nairobi.
Advisor, Biomedical and Clinical Science Working Group of African AIDS Vaccine Program
(AAVP) WHO, UNAIDS.
Advisor / Consultant, National Polio Eradication Expert Committee (NPEC), Ministry of
Health, Kenya.
Advisor, African Childhood Vaccine Program.
Advisor, Merck Vaccine Network – Africa.
Consultant Virologist / Immunologist, Medical Research Council (MRC) UK, on HIV / AIDS
Vaccines in Kenya.
Medical Officer 11 Kapsabet District Hospital, Kapsabet, Kenya.
Medical Officer 1 Machakos Provincial Hospital, Machakos, Kenya.
Board Certified Nephrology & Internal Medicine
Dr. Abeid received his medical degree from the University of Nairobi, college of Health
Sciences in Kenya. He did his internship and residency in internal medicine at GBMC
and John Hopkins in Baltimore, Maryland USA. During his final year of residency, he was
selected to be chief resident in internal medicine residency. Dr. Abeid did his fellowship in
nephrology at Yale University in, New Haven Connecticut-USA. He is board certified both
in nephrology and internal medicine.
Dr Abeid was also a Clinical Assistant Proffessor of Medicine at SUNY Medical School in New
York -USA. Dr. Abeid has also taken a keen interest in hypertension and is a hypertension
specialist certified by American Society of Hypertension (ASH).
He specializes in all aspects of chronic kidney disease, hypertension, polycystic kidney
disease, all modalities of dialysis and care of pre and post kidney transplant patients.
He sees all his patients at MP shah Hospital
Dr Chris is currently the Medical director of MP shah Hospital
Dr. C Abeid
CKD and infectious disease continuum
The talk will focus on relation ship betweek CKD and both chronic infectious diseases (CID) and acute infectious
diaseases(AID).
The question is:Is CKD a risk multiplier for CKD?
Vaccination strategies in CKD will also be highlighted.
Update on Zika virus

SPEAKERS PROFILES & ABSTRACTS I Session IV: Haemorrhagic Viral Fevers
Prof.BhattwasborninKenyaandisaprofessorofinternalmedicineinthedepartmentofclinicalmedicine
andtherapeuticsoftheuniversityofNairobi.Shedidhermastersininternalmedicine fromtheUniversity
ofNairobiandspecializedin tropicalmedicinefromLondonschoolofHygieneandTropicalMedicine.She
didhertraininginbioEthicsfromUniversityofWashington.CurrentlysheisthechairofNationalBioethics
committeeofKenya.ShehasalsobeenamemberofethicscommitteeofKenyaMedicalResearchinstitute
andchairofethicsandresearchcommitteeofuniversityofNairobi. Shehasbeenacouncilmemberof
NationalcouncilofscienceandtechnologyofKenya.Sheisamemberofscientificadvisorycommitteeof
Drugs for Neglected Diseases Initiative. Has been a recipient of staff merit award from the university of
Nairobifortheoutstanding contributiontowardsthemissionoftheuniversity. Shewasawardedelderof
theburningspearbythepresidentofKenyainrecognitionoftheoutstandingcontributiontotheNation
inthefieldofhealth.SheisarecipientofMalariaAfyaawardforcontributiontowardscontrolofmalariain
Kenya.Haswidelypublishedinpeerreviewedjournals andpresentedpapersinnumerousconferences.
HerresearchinterestsareinthefieldoftropicaldiseaseandHIV.
Update on Visceral Leishmaniasis ( Kala-azar)
Visceral Leishmaniasis(VL) is a protozoal infection transmitted by Sand flies ( phlebotomus sp). The disease is
characterized by high fever, weight loss, hepato Splenomegaly and Bone Marrow suppression. It is the second
largest parasitic killer after Malaria.500,000 visceral leishmania cases occur annually and 90% are from India,
Brazil and Sudan.
Visceral Leishmaniasis is recognized as one of the neglected tropical diseases. It is endemic in the East African
region. In Kenya new foci of the disease have come up. In 2003 Leishmania East African Platform (LEAP) was
created which serves as a base for training and evaluation of new treatment. Sodium Stibogluconate (SSG) for
28 days has been the main stay of treatment of VL since 1940. A short course of SSG and Paramomycine(PM)
for 17days was evaluated and is now the first line treatment in the East African region. The other drugs are
liposomal Amphotericine B and Miltefosine the first highly active oral drug for VL.
Diagnosis of VL has been by demonstration of parasites in the bone marrow, splenic aspirate and lymph glands.
Serological tests are also available. More recently a rapid diagnostic test K39 dipstick has been recommended in
endemic areas where facilities are limited.
Work on development is also going on but there is no vaccine yet.
Prof. K Bhatt

Short
CV
for
Kirana
Bhatt,
EBS

Was
born
in
Kenya
and
is
a
professor
of
internal
medicine
in
the
department
clinical
medicine
and
therapeutics
of
the
university
of
Nairobi.
She
did
her

masters
in
internal
medicine

from
the
University
of
Nairobi
and
specialized
i
tropical
medicine
from
London
school
of
Hygiene
and
Tropical
Medicine.
She
did
her
training
in
bio
Ethics
from
University
of
Washington.
Currently
she
is

the
chair
of
National
Bioethics
committee
of
Kenya.
She
has
also
been
a

member
of
ethics
committee
of
Kenya
Medical
Research
institute
and
chair
o
ethics
and
research
committee
of
university
of
Nairobi.

She
has
been
a
coun
member
of
National
council
of
science
and
technology
of
Kenya.
She
is
a

member
of
scientific
advisory
committee
of
Drugs
for
Neglected
Diseases

Initiative.
Has
been
a
recipient
of
staff
merit
award
from
the
university
of

Nairobi
for
the
outstanding

contribution
towards
the
mission
of
the
universi
She
was
awarded
elder
of
the
burning
spear
by
the
president
of
Kenya
in

recognition
of
the
outstanding
contribution
to
the
Nation
in
the
field
of
healt
She
is
a
recipient
of
Malaria
Afya
award
for
contribution
towards
control
of

malaria
in
Kenya.
Has
widely
published
in
peer
reviewed
journals

and

presented
papers
in
numerous
conferences.
Her
research
interests
are
in
the
field
of
tropical
disease
and
HIV.

Dr. M Chakaya
Dr Chakaya Muhwa is a Consultant Chest Physician at the Mater Hospital and the Aga
Khan University Hospital, Nairobi, Kenya. He is the Chief Research Officer at the Centre
for Respiratory Diseases-Kenya Medical Research Institute (KEMRI).
He is also the Chair for the Strategic and Technical Advisory Group, TB -WHO, the DOTS
Expansion Working Group of the Stop TB Partnership and Technical advisor for the
Kenya Association for the Prevention of TB & Lung Disease (KAPTLD). Dr Chakaya has
published over 20 articles in peer reviewed journals. His research interests focus on TB,
Asthma epidemiology and non TB lung infections.
Dr. Madhusudan R. Jaju, Incharge of Medical Intensive Care, Care Hospital, Nampally,
Hyderabad Telangana. Internship: Government Medical College, Aurangabad – 2000
Post-Graduation: K. E. M Hospital, Mumbai – 2004, Critical Care Medicine: NIZAMS
Institute of Medical Sciences – 2009. EDIC: Vienna, Austria – 2013. Consultant & Incharge
ofCriticalCareMedicineatCAREHospitals,HyderabadSeniorResidentatNIZAMSInstitute
of Medical Sciences. Executive member of ISCIM, Hyderabad Chapter
Organising Committee member SZCEC-2016, Hyderabad Chairman of Highlight Sessions
Infection Control Committee member.Dr. R Jaju
New paradigm in the treatment of tuberculosis
Use of immunodulators in Sepsis and Severe Sepsis

Dr.JenniferVeraniMD,MPHleadstheGlobalDiseaseDetection,EpidemiologyandSurveillance
Program for the US Centers for Disease Control and Prevention in Kenya. She is a pediatrician,
epidemiologist, and a Captain in the United States Public Health Service. She obtained her
medical degree from Harvard Medical School, MPH in International Health from the Harvard
School of Public Health, and undergraduate degree in International Development from Brown
University. Dr. Verani completed her residency training at the Children’s Hospital of New York-
Columbia, where she served in the community pediatrics track. Prior to her career in medicine,
Dr. Verani worked for several years on public health programs in Latin America. In 2006 Dr.
Verani came to CDC as an Epidemic Intelligence Service (EIS) officer in the Parasitic Diseases
Branch, where she conducted research on schistosomiasis, lymphatic filariasis, soil-transmitted
helminths, guinea worm, Chagas disease, and Acanthamoeba. Following EIS, she joined the
Respiratory Diseases Branch to work on the prevention of pneumonia and neonatal sepsis.
In that position Dr. Verani collaborated on studies of the effectiveness and impact of vaccines
against Streptococcus pneumoniae and Haemophilus influenzae type B in several countries in
Latin America and Africa, and provided technical assistance for respiratory disease surveillance
in low-resource settings. She led the revision of CDC guidelines for the prevention of neonatal
group B streptococcal (GBS) disease and a multi-state investigation of the remaining burden
of early-onset GBS disease in the United States. In her current position Dr. Verani leads the
Population-Based Infectious Disease Surveillance platform in Kibera and Asembo, and is
establishinganetworkofAcuteFebrileIllnesssentinelsurveillancesitesacrossKenya.Dr.Verani
is also an Adjunct Assistant Professor of Pediatrics at Emory University School of Medicine,
where she helps to train interns who serve patients at an urban primary care clinic.
SPEAKERS PROFILES & ABSTRACTS I Session V: Neglected Infections
Dr. R Virani
Dr. C Mwachari
Dr Christina Mwachari is an Epidemiologist with a clinical microbiology and research
background. She qualified as a Clinical Microbiologist in 1996 and Epidemiologist in
2009. She has over 15 years research experience in infectious disease including, HIV,
TB and diarrheal diseases at the Kenya Medical Research Institute. Currently, she is
working as a Senior Technical Advisor in laboratory for the University of Maryland
Programs in Kenya.

Name
Proﬁle

Chinwendu
Achebe

BSN,
MSN,
ACNP

Chinwendu
Achebe
is
the
Director
of
Nursing
at
M.
P.
Shah
Hospital.

She
schooled
at

Colombia
University
of
School
of
Nursing
New
York
USA.

She
was
previously
a
Clinical

Nursing
Specialist
at
Aga
Khan
University
hospital.

She
has
done
15
years
of
nursing

experience
12
of
which
have
been
spent
working
in
corporate
America.

Chinwe
has
a
Bachelor
Degree
AND
Masters
Degree
in
linguis@cs

Dr.
C.
Mwachari

Chris@na
Mwachari
is
an
Epidemiologist
with
a
clinical
microbiology
and
research

background.
She
qualiﬁed
as
a
Clinical
Microbiologist
in
1996
and
Epidemiologist
in
2009.

She
has
over
15
years
research
experience
in
infec@ous
disease
including,
HIV,
TB
and

diarrheal
diseases
at
the
Kenya
Medical
Research
Ins@tute.
Currently,
she
is
working
as
a

Senior
Technical
Advisor
in
laboratory
for
the
University
of
Maryland
Programs
in
Kenya

Prof.
K.
M.
BhaI

P r o f i l e s

Title Antibiotic Stewardship in the Private Healthcare settings: Lessons Learnt
Author: Christina Mwachari MBChB, MSC, MPH, PhD
Introduction
Introduction: Antibiotic use is the major driver of antimicrobial resistance (AR) worldwide. The inappropriate
use of antibiotics has fuelled the emergence of AR in resource limited settings. Antimicrobial stewardship has
been demonstrated to slow down the spread of AR. This evaluation demonstrates antimicrobial stewardship
experience in the private settings.
Methods: Antimicrobial resistance trends were obtained from selected hospitals from the inception of
antibiotic stewardship committees in 2008. Lessons learnt since the inception of AS for the rational use of
antimicrobials were documented.
Results: Low prevalence of MRSA despite increasing trends of resistance to Staphylococcus aureus. Increased
prevalence of extended spectrum beta-lactamase producing Gram negative organisms among hospital
acquired infections. There was emerging antimicrobial resistance to Carbapenems.
Conclusion: Effective antimicrobial stewardship was associated with reduced hospital acquired infections,
improved selection of empirical antibiotics, reduced overuse of reserved antibiotics through continuous
medical education.
Prevention of pneumococcal diseases and the role of currently available vaccines.

PANELISTS PROFILES
SESSION I I DR. M LUMBA
Dr. Mohan Lumba is a Pioneer Paediatrician in Kenya. He qualified
as a doctor in 1969, specialized in paediatrics in 1972 and received
his Doctorate in Medicine, M.D. Paediatrics in 1974. He joined the
University of Nairobi Medical School as a lecturer 1975 and has been
actively involved in teaching and training paediatricians. He is an external
examiner for both undergraduate and postgraduate paediatric students
at the University. He has published widely in peer review jounals and
has attended and participated in numerous international conferences
and symposiums covering over 18 countries. He is the Chair of the Kenya
Paediatric Association (KPA). He is also the Chairman of the National
Influenza Taskforce and is the immediate past Chairman of the Kenya
Association for the Prevention of Tuberculosis and Lung Disease.
Vice President Pan Africa Thoracic Society.
Medical Practice for over 45 years.
Respiratory Medicine and Infectious diseases/HIV Medicine.
Patron: Kenya Lung Association.
Patron: Kenya Association of Physician.
Chairman: HIV Clinicians Society of Kenya.
Past Chairman of several medical associations and societies.
Overseas Representative - Royal College of Physicians of Edinburgh.
President The Nairobi Club
SESSION V I DR. J OLUOCH

PANELISTS PROFILES
Prof Godfrey Lule currently works as professor of medicine in the
Department of clinical medicine and therapeutics, University of
Nairobi medical school and he is a practicing consultant Physician,
gastroenterologist and thematic head of the infectious disease unit,
Kenyatta National hospital. He is an adjunct professor of infectious
diseases, University of Texas Medical Branch,Galveston since 2010
and University of Maryland, Baltimore since 2013. He runs a part
time private practice at the Nairobi hospital as a consultant physician,
gastroenterologist and infectious disease specialist.
His main area of interest has been hepatitis and HIV. He has written over
60 original research papers in various journals in addition to editing a
textbook on Colonic Disorders and is author to several chapters in a few
other textbooks.
SESSION IV I PROF G LULE (FRCP E)
Dr. Adam received a Doctor of Medicine degree from the University of
Illinois followed by training in internal medicine and infectious diseases
at the University of Arizona followed by molecular parasitology training
attheNationalInstitutesofHealth.HejoinedthefacultyoftheUniversity
of Arizona College of Medicine where he worked as a Professor of
Infectious Diseases and Microbiology / Immunology until 2011. He was
a Fulbright scholar at the University of Nairobi in 2011 and then joined
the AKUHN faculty in April 2012 as a Professor of Pathology in clinical
microbiology. He is currently leading the effort to expand molecular
diagnosis at AKUHN and is chair of the research committee and the
infection control committee. He has been involved in numerous basic
and clinical research related projects primarily in molecular parasitology
and fungal infections.
SESSION II I PROF R ADAM

Prof Gunturu Revathi is Associate Professor of Microbiology at the
Aga Khan University Hospital, Nairobi. She is also a visiting faculty at
the University of Nairobi and the Jomo Kenyatta University of Science
and Technology. She has 25 years of professional experience having
worked in the Cytology Research Center at the Maulana Azad Medical
College, New Delhi, Dept. of Microbiology, the University College of
Medical Sciences, New Delhi before moving to Kenya. She headed the
department of laboratory medicine at the Kenyatta National Hospital for
5 years while being a faculty member of the Department of Medical
Microbiology at the College of Health Sciences, Nairobi .She is a visiting
scientist at the Kenya Medical Research Institute where she was co-
investigator in 3 research projects. Prof Revathi has supervised 45 post
graduate dissertation projects throughout her career and published 60
papers in peer reviewed journals. She is a member of several national
and international professional bodies such as ISID, ESCMID, ERS, KACP,
APECSA, GARP and KMA. She is also on various National committees
such as KAPTLD, Technical advisory committee for National Program for
Tuberculosis and Leprosy, National committee on Infection prevention
and control, Kenya National committee on Infectious and Parasitic
Diseases Research Program (IPDRPC), Member of National working
group for Clinical Management and Referral guidelines of Ministry of
Medical services, Republic of Kenya.
SESSION III I PROF G REVATHI
Dr Saha (MD, MRCP) is a senior lecturer in medicine at Aga Khan Hospital,
Nairobi.
He has a large ecperience in Internal Medicine and runs an actve practice
in Nairobi for over25 years.
His main areas of interest are noninvasive cardiology, gustroentology
and intensive care medicine.
PANELISTS PROFILES
SESSION V I DR. H SAHA

SESSION III I DR. A K SHAH
Fellow of the International College of Surgeons.
Honorary fellow of the Society of Eye Surgeons and the International
Eye Foundation.
Fellow of Eastern Africa College of Ophthalmologists.
Member of the Executive Council of the Ophthalmological Society of
East Africa.
Conferred with the Honour of Moran of the order of the Burning
Spear (MBS).
Member of the Board of Governors of The Social Service League and
MP Shah Hospital.
Divisional Surgeon of The St. John Ambulance Brigade.
Technical Advisor for the Sightfirst programme - Africa region.
Member of the National Prevention of Blindness Committee of the
Ministry of Health, Government of Kenya.
Professional training: Post-graduate Diploma in Paediatric Infectious
Diseases, University of Oxford 2014, MSc Paediatrics and Childhealth,
University of Nairobi 1985.
Practice: Private practice in Nairobi.
Appointments: Consultant for HIV services in Gertrude’s Garden
Children’s Hospital. Honorary lecturer department of Paediatrics and
Childhealth, University of Nairobi.
Member of: National Technical Working Group NASCOP, for development
of National HIV guidelines and management of ART 2nd line failure cases
TWG Kenya Essential Medicines List 2016.
National Polio Experts Committee for Kenya and Somalia
Current Research activity: Site PI Gertrudes Hospital for LIVING study
(Lopinavir sprinkles)
SESSION I I DR. J MBUTHIA
PANELISTS PROFILES

Dr. Dhirane Shah qualified in Internal Medicine from M.P. Shah Medical
college, 1990.
Currently a consultant physician practicing as a hospital physician at
The M.P. Shah Hospital
and a private practitioner at both The M.P Shah Hospital and The Aga
Khan University Hospital.
He has a special interest in Cardiology.
Dr. S. T. Patel
Dr Surendra Patel is the eve
physician with an established p
He is currently Adjunct Profe
physician to diagnose and tr
treatment of HIV & AIDs patie
research projects in his field
facilitated availability of anti re
He is also a member of various
& AIDs.
PR
Dr. Dhirane Shah
Dr. Dhirane Shah qualified in In
Currently a consultant physicia
and a private practitioner at bo
He has a special interest in Car
Dr. Omonge is qualified in MBCh
SESSION II I DHIRANE
Consultant Physician and Cardiologist, head of cardiology MP Shah
Hospital, Nairobi Kenya. Consultant Physician and Cardiologist at
the Forces Memorial Hospital Nairobi Kenya. Consultant Physician
Equator Meridian Hospital Nairobi. Consultant physician naval hospital,
Mombasa. Part-time/locum physician at the Agha Khan University
hospital Nairobi, Pandya and Mombasa hospitals in Mombasa. Visiting
Physician of the AMREF flying doctor services. Senior House Officer
in the department of Internal Medicine, University of Nairobi at the
Kenyatta National Hospital. Senior Medical Officer at the Nyali Barracks
in Mombasa. Medical officer in the Ministry of Health at Kitale District
Hospital. Internship training at the Moi Refferal and Teaching Hospital
Eldoret.
SESSION IV I DR. B SAMIA
PANELISTS PROFILES

Suryakalaben Maganlal Chandaria Children’s Medical Centre
M. P. Shah Hospital has set up a brand new state of the art Children’s Hospital in Nairobi. The new ‘Suryakalaben
Maganlal Chandaria Children’s Medical Centre’ is an ultramodern facility offering critical care inpatient and out-
patient services for children. The unique 5 story children’s hospital has 30 rooms specially designed to meet
the needs of the patients, the family and the caregiver and at any point of time it can accommodate up to 50
inpatients. All medical supplies are built into the wall behind the patient to allow for sophisticated bedside
technology. Each has got attached bathroom with all modern amenities. The rooms in each floor are designed in
a way to take care of children below two years and above. The Paediatric Intensive Care Unit (PICU) / Neonatal
Intensive Care Unit (NICU) and Paediatric High Dependence Unit (HDU) are staffed by highly trained doctors and
nurses who specialize in caring for critically ill patients. This ICU has a higher staff-to-patient ratio and access
to advanced medical resources. Common conditions that are treated within this ICU include- Acute respiratory
distress syndrome, trauma, multiple organ failure and sepsis. Patients may be transferred directly to an intensive
care unit from an emergency department if required, or from a ward if they rapidly deteriorate, or immediately
after surgery if the surgery is very invasive and the patient is at high risk of complications. The new ICU is
equipped with the latest emergency response monitors, defibrillators, ventilators etc. Each patient has a bedside
and centralized cardiac monitoring system. The new ICU beds are designed to keep patients both safe and
comfortable. Each room is very spacious with full glass walls, all the equipment are wall mounted so as to keep
the floor clean and infection free.
The following services are currently offered at the Suryakalaben Maganlal Chandaria Children’s Medical Centre:
1. Well Baby Clinic 6. Children’s Sub Specialty clinics
2. Vaccination Centre 7. Pediatric Intensive Care Unit
3. Neonatal Intensive Care Unit 8. Pediatric High Dependency Unit
4. Dedicated pediatric pharmacy 9. Diagnostics – Pathology Lab & Radiology Services
5. In patient rooms for Children-dedicated below 2 years & above
M. P. SHAH HOSPITAL

The New Dr. Kanubhai Babla Intensive Care Unit
The M. P. Shah Hospital’s Dr. Kanubhai Babla Intensive Care Unit (ICU) is located on the ground floor of the
Dr. Kanubhai Babla Medical Centre. It is a specially designed 7 bed rooms (of which 2 are isolation rooms
with negative pressures) that deals with patients with high risk for actual or potential life threatening health
problems. Working in ICU requires a lot of focus and stamina but very satisfying. Dealing with critically ill
patients requires continuous monitoring of every detail of the patient’s hemodynamic parameters, physiological
processes like voiding and breathing to their medication and interacting with their relatives and keeping them
up to date and reassured at all times. Empathizing with their relatives and understanding the constant worries
and anxiety concerning the patients and giving them all the available options. Being there for the critically
ill and helping them overcome the stress related to disease responses, pain free and still maintaining their
dignity and decency. Because of the delicate balance of the critically ill patients, the care delivered must
include collaboration of all the other discipline involved in care of consistent approach based on knowledge
and skill. They include physicians, critical care nurses, anesthetists, physiotherapist, pharmacists, nutritionists
and pathologists. Although critical care unit is a very stressful place, staffs help each other in stress coping
mechanisms that make it remain the most satisfying department to work in!
the art Children’s hospital
4 hours casualty, Well-baby
ecialty clinics, NICU, PICU &
the art, most modern
Unit and High Dependency
the region, at the ground
ubhai Babla Medical Center.
nter with specialized cardiac
d state of the art Cath Lab
s of interventional cardiac
and private rooms at the
oor of Dr. Kanubhai Babla
oor theatre at the 1st ﬂoor
Babla Medical Center.
RI, 128 Slice Cardiac CT Scan,
ay, Mammography, 4D
d OPG units in the radiology
matology analyzer, New fully
chemistry equipment, Fully
robiology unit & automated
units in the Pathology Lab.
and orthodontic specialties.
Brand new ENT center with all modern
equipment and Audiology Unit.
A modern wound management clinic and
trauma center at the Accident and
Emergency unit.
Renal center with advanced Dialysis units,
CRRT machines and Kidney transplant unit.
We do all kind of Orthopedic implants,
replacement surgeries, Neuro & Spine
procedures
Our Maternity center gives birth to on an
average 150 babies every month.
Our Accident & Emergency unit receives
around 6000 patients every month.
We perform around 5000 diﬀerent kinds of
lab tests available in this world.
We have state of the art oncology
management unit with Chemotherapy,
Oncology surgeries, in patient
management & Palliative care.
We have 3 Tesla MRI, 128 Slice CT Scan, 4D
Ultrasounds, digital Mammography, X-Ray
& OPG
MRI ICU Executive Room
Grand EntranceWell Baby Clinicntre
M. P. SHAH HOSPITAL

M. P. SHAH HOSPITAL
Cardiology Unit and Cath Lab
M.P Shah Hospital has invested in a Cardiology unit with a modern state-of-the-art catheterization laboratory
(Cath-Lab) which is located on the 4th floor of the Dr. Kanubhai Babla Medical Centre. The Cath Lab is fitted with
high end diagnostic imaging equipment. The M.P Shah Hospital Cath lab is staffed by a multidisciplinary team
who are able to conduct the following procedures:-
• Coronary Angiography or Coronary catheterization
• Coronary Angioplasty or Percutaneous coronary
• Intervention / PCI
• Closure of some congenital heart defect
• Treatment of stenotic heart valves
• Permanent and temporary pacemaker implantations
• Electrophysiological studies such as AV node
• Ablation
• Rot ablation of heavily Calcified vessels
• Left and right Sided pressure studies
The cardiac clinic is a state of the art facility offering all forms of diagnostic, therapeutic and intervention services
related to cardiovascular and metabolic diseases. It prides of bringing in the latest unparalleled technology in
management of cardiovascular diseases.
The clinic offers the following services:
• Full time cardiology consultations
• ECG services
• Holter monitor services
• Ambulatory BP monitor services
• StateoftheartEchocardiographywith4Dapplication,bothtransthoracicandtransesophageal.
Portable echo services for ICU, wards, theatre are also done.
• Stress Test services, via Stress or Pharmacological modes

A brand new dental Centre
M.PShahHospitalhassetupabrandnewdentalcentre
with the aim of incorporating the best new dental
technology into the state of the art practice, making it
one of the most advanced centers in the country. This
new cutting edge technology includes:
• AninternationallyrecognizedmaxillofacialSurgeon
who specializes in treating diseases, injuries and
defects in the face, jaws, hard and soft tissues of
the Oral (mouth) and Maxillofacial (jaws and face)
region.
• An internationally recognized orthodontic surgeon
who has specialized in preventing, diagnosing and
treating dental irregularities.
• 2 General Dentist
M.P. Shah dental centre is excelling in the field of
Dentistry every year for more than a decade now. Here
we believe newer techniques, technology and our
perseverance bring us close to perfection in our work.
Our centre provides the finest Dental Services with
state-of-the-art equipments, you name it we have it!!
This is a place where each one of us believes Dentistry
is our passion and patient care is our utmost concern.
Wonder why we are different from the rest of the
others! There is just one difference: Our expertise
guarantees that you leave with a healthier, more
beautiful smile. Our wide range of dental treatments,
tailored to both Children and Adults, includes all types
braces treatment like aesthetic braces, invisible braces
(lingual) , invisalign ( clear aligners), self ligation braces
treatment, functional appliance and orthopedic
treatment. Wide range of maxillofacial surgery like
trauma, cancer surgeries. Orthognathic ( cosmetic
face surgery), TMJ problems . treatment of snoring
and obstructive sleep apnoea, Single Sitting RCTs,
periodontal Laser therapy, Smile enhancements, Teeth
Whitening, Dental Implants, Metal free, Aesthetic
crowns, bridges and Veneers, being our Speciality.
CONSULTANT ORAL & MAXILLOFACIAL SURGEON
AND HEAD OF DENTAL DEPARTMENT
Dr. Shalender Sharma
HejoinedM.P.ShahHospital
as a Consultant Oral and
Maxillofacial Surgeon on 1st
June 2016. Dr. Shalender
holds a Bachelor degree
in Dentistry (B.D.S) from
Kurukshetra University,
M.M Dental College, Ambala, Haryana and Masters
in Dentistry (M.D.S) from Tamilnadu University,
Ragas Dental College, Chennai among several other
professional certifications.
He has over 11 years of experience in Dentistry, Oral
& Maxillofacial Surgery. Prior to his appointment,
he was working as a Specialist Maxillofacial Surgeon
in Botswana. He has previously worked as a Senior
lecturer in M.M Dental College, Ambala, Haryana &
Teerthanker Dental College in Moradabad, India. He
also worked as Associate Professor in the Department
of Oral and Maxillofacial Surgery in STG Dental College,
Gurgaon, India.
He is a Specialist in Maxillofacial trauma, dental
implants, maxillofacial pathology(oral cancer), cleft
lip and palate, orthognathic surgery, T.M.J disorders
among other procedures. Dr. Shalender has 21
publications 15 of which are national and 6 that are
international. He is a member of the Association of
Oral and Maxillofacial Surgeons of India (AOMSI) and
member of the Indian Dental Association.
M. P. SHAH HOSPITAL

M. P. SHAH HOSPITAL
CONSULTANT ORTHODONTIST
Dr. Kaberi Majumder
She joined M. P. Shah Hospital as a Consultant
Orthodontist on 1st June
2016. Dr. Kaberi holds a
Bachelor degree in Dentistry
(B.D.S) from Rajuv Gandi
University of Health Sciences
India and Masters in Dentistry
(M.D.S) from The Tamilnadu,
Dr. MGR Medical University
among several other professional certifications.
She has has over 11 years of experience in Dentistry
and Orthodontics. Prior to her appointment, she was
a Reader in Dashmesh Institute of Dental Science,
Faridkot. She also previously worked as a Senior
Lecturer in SGT Dental College and Teerthanker
Mahaveer Dental College. She has also practiced as a
Consultant Orthodontist at the Max Hospital in New
Delhi and Park Hospital in Gurgaon.
Dr. Kaberi has 15 publications 8 of which are national
and 7 that are international. She is a member of the
review board of the Indian Journal of Dental Science
and Research and a Co-Editor of the Dental Showcase
bulletin by Teerthanker Dental College.

M. P. SHAH HOSPITAL
Executive Pavilions and VIP rooms
At M.P. Shah Hospital, we understand some patients desire an additional level of luxury and comfort during
their hospital stay. The Hospital has recently opened Executive and V.I.P rooms at the 2nd and 3rd Floors of
Kanubhai Babla Medical Centre, allowing patients and their families to experience a level of customized service
and comfort in a relaxing and private environment. The rooms combine the comfort of knowing you have
chosen the best possible medical facility with a touch of luxury to enhance quick recovery.

Wound Management Clinic
M. P. Shah Hospital now has a Wound Care Center which is one of its kind in the region. The M. P. Shah Hospital
Wound Care Center was inaugurated on 13th may 2016 by Prof. Khainga.
MP Shah Hospital is the first hospital to have this high standard facility in the country. The department is located
in the accident and emergency department. It is equipped with high quality dressing materials, suitable for all
kinds of wounds. The unit is headed by the nurse in charge who coordinates the operation of the unit.
Dressings are done on appointment basis to enhance proper and early preparations for the patients and materials
to be used. A schedule is in place to accommodate the patients’ needs to enhance patient delight. Dressing
of the wounds is done by the specialty nurses in A&E in collaboration with the A&E doctors and in constant
consultation with the surgeons where need arises.
The materials we use are as follows;
1. For debridement – intrasite gel for autolytic debridement, iruxol for conservative sharp enzymes, and
adsorb for chemical debridement and versa jet for surgical debridement.
2. For bacterial balance – acticoat, allevyn and bactigrass
3. For inflammation reduction – monocrystalline silver which helps reduce the bacterial load in the wound
which is causative of prolonged inflammation
4. For moisture maintenance – elect foam, allevyn, and opsite flexi grid and opsite post –op.This maintains
the appropriate moisture levels to help facilitate healing
5. For advance closure – opsite flexigrid and secura.
We look at at our patients comprehensively by identifying the factors that delay proper wound healing for
example their nutritional status, any underlying medical conditions e.g. cancer or diabetics, age, cause of the
wound, compliance to antibiotics and other medications, environment and materials used for dressing.
In view of all this, we give our patients a detailed health education based on assessment and identified individual
problems.
We not only address patient wounds but also give psychosocial support to enable a holistic approach to the
healing process.
M. P. SHAH HOSPITAL

Magnetom Spectra 3Tesla MRI Equipment from Siemens
The Hospital is acquiring a state of the art, sophisticated; most advanced Magnetom Spectra 3Tesla MRI
Equipment from Siemens in the 2nd week of August. This MRI is going to be the best in the region, designed
with patients’ comfort in mind, while incorporating image quality, this MRI will boost the Radiology Department
tremendously. The MRI will improve the quality of patient care leading to faster and more accurate diagnoses
and more specific treatment of medical conditions. The system offers unprecedented access to 3 Tesla Magnetic
resonance imaging. It is the key to a new scope of image and diagnostic confidence for physicians. This will be
the first machine with such technology of its kind in Africa.
M. P. SHAH HOSPITAL

Jamal Devji Family ENT Centre
In order to remain consistent in providing quality healthcare the Hospital is in the process of acquiring a state
of the art ultramodern Ear, Nose and Throat / Head and Neck Clinic to provide the much needed services to its
patients. The centre will be providing diagnosis, evaluation and treatment of both common and highly complex
ENT disorders, as well as diseases affecting the head and neck. The centre will be run by a professional team of
doctors and nurses dedicated towards offering the latest treatment options to patients.
· General ENT examinations
· Endoscopic examinations: Nasal endoscopy, video-otoscopy and Laryngoscopy
· Videostroboscopy and voice management
· Pure Tone Audiometry and Tympanometry
· Hearing AID fitting and dispensing
· Nystagmograhy and vestibular rehabilitation
· Microscopy
· Ear Syringing
· Basic minor surgical procedures
· Sleep studies
Quadruple endoscopy centre with 4 light
outlets, each 150 W halogen or LED light, light
barrier controlled lighting, automatic
All handpieces and applied parts are fully
autoclavable (water handle, spray handle, spray
cannulas, nozzles etc.). Quick-fit
To enlarge the workspace, a swivel support
is available to integrate a stroboscope,
ultrasound unit etc.
Details
re fully
handle, spray
To enlarge the workspace, a swivel support
is available to integrate a stroboscope,
ultrasound unit etc.
All handpieces and applied parts are fully
autoclavable (water handle, spray handle, spray
cannulas, nozzles etc.). Quick-fit
To enlarg
is availab
ultrasou
Details
M. P. SHAH HOSPITAL

MATERNITY CENTRE
ANTENATAL BOOKING
AND MATERNITY EDUCATION
We provide a range of education
programs to inform and empower
you as you approach the birth of
your baby.
PACKAG
ES
Pregnancy Choices of Maternity Care
M.P. Shah Hospital
acknowledges that pregnancy is
an exciting time for women and
their families and oﬀers a range
of services to meet your
individual needs.
At M. P. Shah Hospital, you
have a variety of choices of
maternity care available to you.
Your choice will depend on:
• Your wishes
• Issues that arose in a previous
pregnancy
• Any medical conditions that
you now have
• Conditions that may arise in
this pregnancy
• Where you reside.
Your choices include:
• Hospital Doctor based care
• Midwifery care
• Private obstetric care.
Professional Services In All Spheres Of Healthcare
Packages
Non stress test
CSSD and Drugs
Pediatrician’s charges
Baby bills
Receiving of baby
Physio
2 days admission
Sterlization charges
Nursing charges
Doctor delivery charges
Doctor’s visit
Labor room charges
Delivery Charges
5 days admission Sterlization charges
Nursing charges Doctors visit
Surgeon’s fees Anaesthetic charges
Theatre pack CSSD and Drugs
OT charges Pediatrician charges
Normal delivery supervised by Doctor
NB: To qualify for the package, the full package amount
must be paid upfront before 30 weeks gestation
EMERGENCY CEASERIAN IS NOT COVERED WITH THIS PACKAGE THE FULL BILL IS
PAYABLE BY THE PATIENT
Please note mothers sanitary pack is charged extra over and above the package price,
baby items pack is also available with additional charge
Please note mothers sanitary pack is charged extra over and above the package price,
baby items pack is also available with additional charge
Caesarean section
Receiving baby
Baby bills
Non stress test
Physio
210,000/=
95,000/=
.......................................................................
PLEASE NOTE THAT YOU MUST SUBMIT YOUR NHIF CARD OR PAY CASH
Admission more than 2 days bills for NORMAL DELIVERY to be paid in full
from the 3rd day.
Admission more than 5 days bills for CAESAREAN SECTION to be paid in full
from the 6th day.
Vacuum, complicated delivery, twins/breech delivery or instruments used
for delivery are an additional charge of
27,000/=
PLEASE NOTE THE PACKAGE MAY CHANGE ACCORDING TO THE TYPE OF
DELIVERY AND THE OUTCOME. YOU MAY BE REQUIRED TO PAY
ACCORDING TO THE PACKAGE YOU FALL IN AT THE TIME OF DELIVERY.
ANY INVESTIGATIONS e.g. ULTRA SOUND, BLOOD GASES FOR ANTENATAL
PROFILE ETC. WILL BE CHARGED SEPERATELY.
RESACITATION OF NEWBORN WILL ATTRACT ADDITIONAL CHARGES.
NO REFUNDS ARE GIVEN AS THIS IS A PACKAGE PRICE
Flexible solutions for
Your maternal needs,
Comfortable and
Affordable accommodation
For you and your child
: DL: :020 4291621 / 020 4291622 / 020 42910629 / 020 4291000
0722 783 350 / 0733 606 752 / 0733 606 113
maternityfair@mpshahhosp.org / info@mpshahhosp.org
M.P. Shah Hospital @MPShahhospital
www.mpshahhosp.org
IMPORTANT NOTICE

Pulling patients from
the depths of serious infection
Meronem™ IV (Injection). Meronem IV injection contains meropenem 500 mg or 1 g as the trihydrate blended with anhydrous sodium carbonate for constitution. Each gram of meropenem (anhydrous
potency) contains 208 mg sodium carbonate. PHARMACEUTICAL FORM: Sterile white powder for solution for intravenous injection of infusion. THERAPEUTIC INDICATIONS: Treatment, in adults
and children, of the following infections caused by single or multiple bacteria sensitive to meropenem: Pneumonias and Nosocomial Pneumonias, Urinary Tract Infections, Intra-abdominal Infections,
Gynaecological Infections, such as endometritis and pelvic inflammatory disease, Skin and Skin Structure Infections, Meningitis, Septicaemia, Empiric treatment, for presumed infections in adult patients
with febrile neutropenia, used as monotherapy or in combination with anti-viral or anti-fungal agents. Meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment
of polymicrobial infections. For full prescribing information refer to the package insert approved by the medicines regulatory authority. AstraZeneca Pharmaceuticals (Pty) Ltd. Reg. No. 1992/005854/07.
Building 2, Northdowns Office Park, 17 Georgian Crescent West, Bryanston, 2191. Private Bag X23, Bryanston, 2021, South Africa. Tel: +27 (0)11 797-6000. Fax: +27 (0)11 797-6001. www.astrazeneca.
com Meronem is a trademark of the AstraZeneca Group of Companies. Expiry Date: March 2018. Activity ID: 762695.
References: 1. Unal S, Masterton R, Goossens H. Bacteraemia in Europe—antimicrobial susceptibility data from the
MYSTIC surveillance programme. International Journal of Antimicrobial Agents 2004, 23:155–163. 2. Rahal JJ. The
role of carbapenems in initial therapy for serious Gram-negative infections. Critical Care Medicine. 2008;12(Suppl
4):S5 (doi:10.1186/cc6821).
1
MeronemTM
optimise outcomes – every hour counts2

SPEAKERS PROFILES & ABSTRACTS I Session III: Bacterial Infections
For more than 150 years, a very special passion has driven the people of MSD. Our goal is to
develop medicines, vaccines, and animal health innovations that will improve the lives
of millions. Still, we know there is much more to be done. And we’re doing it, with a long-
standing commitment to research and development. We’re just as committed to expanding
access to healthcare and working with others who share our passion to create a healthier world.
Together, we’ll meet that challenge. With all our heart.
MEDICAL BREAKTHROUGHS MAY COME OUT OF THE LAB.
BUT THEY BEGIN IN THE HEART.
Copyright © 2014 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA All Rights Reserved.

NAIROBI ENTERPRISES LIMITED (NEL) was established in Nairobi in 1978. It is a limited company owned by the
Dhanani family. Currently located at SAACHI PLAZA, GROUND FLOOR B-WING B1 ARGWINGS KODHEK ROAD
KILIMANI PAST YAYA CENTRE.
At Nairobi Enterprises Ltd we are committed to delivering quality equipments for the region with a focus to
guarantee our clientele excellent quality products and service.
Nairobi Enterprises Ltd is one of the Major distributors of medical Equipment, veterinary medicines and feeds
supplements in the East and central African regions.
Our aim in veterinary is to offer quality, affordable products and professional services to our farmers.
NEL has the widest choice of Equipments backed by the most skilled technical back-up in the region.
NEL has been the market leader in PSA oxygen systems and dental units in the region. NEL employs 53
permanent staff in various departments. Annual turnover is approximately 74 million dollars.
Sister companies owned by the same family include Universal Corporation Ltd and Chemoquip Ltd among
others.
Our strength in the market is our ability to provide back-up service for the equipment we supply. Many of our
customers are on service contracts for larger equipments such as oxygen generators, Concentrators, dental
units Etc. The equipments therefore give longer life and fewer interruptions.
Our other strength is training our customers to understand as much about technical details of our equipments
as possible. Whenever we undertake installation of our Equipment we want to do it with the customers
representatives so that the customer is familiar with the equipment.
During the last decade NEL has taken consistent steps to add value to relevant products and innovative
solutions. Nairobi Enterprises Ltd meets quality benchmarks and retains cost effectiveness to compete with
the best in the world.
Our huge product portfolio includes; Oxygen generators and concentrators, Dental units, Hospital furniture,
Anaesthesia machines, Autoclaves and sterilizers, Baby Incubators, BP Machines, Diagnostics, Disposables and
dressing, Surgical Instruments, Hollow ware, Ultra sound scanners, Doppler’s, Patient Monitors, Diathermy
Machines, ECG machines, Nebulizers, suction Machines, Orthopedic implants and items, Pulse Oximeters,
scales instrument sets, Sutures, Theatre, Packaging Materials required in Medical Fraternity among many
others.
NAIROBI ENTERPRISES LIMITED also offers Equipments on Rental Basis and hire purchase subject to set terms
and conditions.
NAIROBI ENTERPRISES LIMITED Mission is to provide affordable good quality medical equipments while its
vision is to be the medical equipments provider of choice within the East and central African region and
beyond.
Nairobi enterprises Ltd is therefore your one stop medical shop for all you medical items requirements and
Pharmaceuticals. We are authorized distributor of Fresenius Kabi Oncology Ltd formely Dabur Pharma Ltd
India, Bharat Serum and Vaccines Ltd, Airsep, Gnatus products.
NELNairobi Enterprises Limited
Glenmark Pharmaceuticals Key Products
Glevonix 500 mg Tablets / IV
Lizolid 600 mg Tabs / IV
Esose 20 mg / 40 mg
Flexilor P / P8
Zupricin
Momate
Ibicar s
Canditral
Saferon Syrup / Tablets
Ketoplus
Since 1948 Denk Pharma
products are …
 Registered
 Manufactured
 Quality controlled
… in Germany!
Analgesics
Antiallergics
Anti-infectives
Antimalarials
Cardiovascular drugs
Dermatologic drugs
Food Supplements
Gastro intestinal drugs
Metabolic drugs
Minerals & Vitamins
Oncology
Respiratory drugs
Our therapeutic areas:
Contact us: www.denkpharma.de Distributors: Laborex ltd, Omaera Ltd, and
Symbio Ltd
Quality and affordable branded generics
Available to our patients;
1. ANDARAN 150MG 30FCT EAC (IRBESARTAN)
2. ANDARAN 300MG 30FCT EAC
3. ANDARAN 75MG 30FCT EAC
4. ANDARAN HCT 150+12.5MG 28FCT EAC
5. ANDARAN HCT 300+12.5MG 28FCT EAC
6. BANEOCIN 20G OINTMENT (BACITRACIN/NEOMYCIN)
7. BIODROXIL 125MG 60ML POS (CEFADROXIL)
8. BIODROXIL 250MG 60ML POS
9. BIODROXIL 500MG 12’s
10. PEROMENE 1G 10’s (MEROPENEM)
11. PEROMENE 500MG 10’s
12. PIP/TAZO SDZ 4G/500MG 1PSOIJ EAC
(PIPERACILLIN/TAZOBACTUM)

Profile of GlaxoSmithKline Pharmaceutical Kenya Limited
GlaxoSmithKline (GSK) is one of the world’s leading research-based pharmaceutical and
healthcare companies. We have a challenging and inspiring mission to improve the quality of
human life by enabling people to do more, feel better and live longer. The company is
headquartered in the UK with major business operations in the US and employs 99,000 people in
120 countries.
In East Africa the company started operations in 1956, then as Burroughs Wellcome. The
headquarters for the East Africa business is based in Nairobi, serving key countries in East Africa
for example Ethiopia, Djibouti, Uganda, Rwanda, Tanzania and Kenya.
GSK’s business in East Africa is unique, as our manufacturing site, consumer healthcare and
pharmaceutical operations are all based at our Likoni Road facility in Nairobi. The company has a
workforce of 323 people in the region.
On 2nd March, GSK (globally) announced it concluded its three-part transaction with Novartis
involving our Consumer Healthcare, Vaccines and Oncology businesses:
• GSK and Novartis have combined their consumer healthcare and over-the-counter (OTC)
businesses, respectively, to form a new company, called GSK Consumer Healthcare
• GSK has acquired Novartis’global Vaccines business, excluding influenza vaccines
(except in China, where GSK bought Novartis’flu business)
• Novartis acquired GSK’s marketed Oncology portfolio and associated R&D activities.
The transaction has enabled GSK to substantially strengthen two of its core businesses – Vaccines
and Consumer Healthcare – through scale and focus, release further value to shareholders and
delivering far-reaching benefits to patients and consumers.
In view of the transaction, a new trading entity called GlaxoSmithKline Pharmaceutical Kenya
Limited was created. GSK business in Kenya and East Africa as at 1st July 2015 separated such that
the Pharmaceutical business now trades under GlaxoSmithKline Pharmaceutical Kenya
Limited while the Consumer Healthcare and Manufacturing business continues to trade under
GlaxoSmithKline Limited.
In connecting with our communities, the company has made a commitment to donate
albendazole for the school deworming programmes in public schools and to work with the World
Health Organization to eradicate lymphatic filariasis through the albendazole donation
programme by 2020. In partnership with Save the Children and Amref Health Africa, we are
contributing to improving maternal health and strengthening the health system by training
health care workers.

OVERVIEW
Aurobindo Pharma Limited was founded in India year
1986.The company is worth over 1 billion USD with a
strong focus on R & D and globally accredited
regulatory agencies approved plants.
Aurobindo offers a large product portfolio of over
400 products covering a wide range of therapeutic
segments such as neurosciences, cardiovascular,
anti-retroviral, anti-diabetics, gastroenterology and
cephalosporin’s, among others.
Aurobindo is emerging stronger in Africa, Asia,
Middle East, CIS and Latin America and exports to
over 125 countries across the globe. The company
strives hard to provide world-class quality medicines
at affordable prices with a strong commitment
towards healthier life.
On behalf of Getz Pharma, I would like to commend the M.P.Shah hospital
for organizing this year’s Infectious Diseases Forum. I am sure this
conference objective is to provide a platform on which the Physicians and
Infectious disease specialists can share practical and local experiences in
prevalence, control and treatment options for infectious Diseases.
Getz Pharma has continued to partner with M.P Shah Hospital and other
health providers in availing our world class Branded Generic Medicines at
affordable prices and superior quality. In this regard, in 2014 Getz Pharma
achieved the WHO prequalification of our quality Control laboratory at the
manufacturing facility, making us the one of the 38 with such accreditation
worldwide. Additionally, we are among the few companies in the region to
achieve the PIC/s GMP recognition.
We wish all the delegates a good learning experience during the conference.

Whoweare:
PfizerLaboratoriesLimitedisawhollyownedsubsidiaryofPfizerIncorporated,New
York,theworld’slargestbiopharmaceuticalcompanyestablishedin1849.
HistoryinNigeria&EastAfricaRegion(NEAR):
PfizerstartedoperationsinAfricain1957withNairobibeingtheregionalheadoffice
forAfricaandtheMiddleEast. Itthensetupasecondpharmaceuticalplantforthe
West African sub-region in 1976 at Oregun, Lagos, manufacturing, marketing and
distributingPfizerbrandsofPharmaceuticalandVeterinaryproducts.Thecompany
alsohadmanufacturingoperationsinNairobi,Kenya.
PfizerNEARToday:
Today, Pfizer NEAR continues to maintain a significant presence in Nigeria, Ghana
andtheEastAfricanRegion(NEARMarkets)thatdatesbackto1950s,operatingwith
Headquarters for Pfizer (NEAR) – Nigeria, Ghana, and East Africa in Lagos.
Co-ordination of medical operations in the region and marketing of other new
productsfromPfizerResearch&Developmentefforts.
KeyTherapeuticAreas:
Pfizer has significant presence in cardiovascular disease areas with its key brands
such as Norvasc and Lipitor. Other disease areas where the company contributes
significantlyincludepainandanti-infectives.WiththeacquisitionofWyethbyPfizer
Inc., Pfizer expanded into the new area of vaccines. The Pneumococcal Vaccine,
Prevenar 13, being the first vaccine launched by Pfizer in the NEAR market is a
strategic preventive intervention against pneumonia - the cause of an average of
20%deathsofchildrenunderfiveinNigeria.Othertopoftherangebrandsinclude
Viagra, Neomedrol and Depo Provera. In addition to our commercial activities in
Nigeria, Pfizer has created direct employment for over one hundred people and
indirect employment for another 250 people, Pfizer invests in every community
where it has operations. This is in line with our core value of “Working together to
maketheworldahealthierplace”.Someoftheseactivitiesinclude:
•InternationalTrachomaInitiative(ITI)
ITI is a partnership between Pfizer and the Task Force for Global Health, which
supports the goal of eliminating blinding trachoma, the leading cause of
preventableblindness,by2020.PfizerdonatesZithromax*(anantibiotic)forthefree
management of trachoma, a leading cause of blindness in Nigeria. Pfizer has
providedcloseto225millionZithromax*treatmentstotalingalmost$5billionUSD
forusein19countries.
•DiflucanPartnershipProgram
Pfizer created the Diflucan Partnership in 2000 to improve the quality of life for
people living with HIV and AIDS. Pfizer and its partners distributed millions of
Diflucan (Fluconazole) treatments for two AIDS related fungal infections in Nigeria,
Kenya,TanzaniaandUganda.
•InfectiousDiseasesInstitute
PfizerandotherpartnersestablishedtheInfectiousDiseasesInstitute(IDI)inUganda
in2004.TheIDI,amajormedicaltrainingandresearchcentreheadquarteredwithin
Uganda’s Makerere University, aims to improve health in Africa by training medical
professionals and providing them with skills and resources to use in their
communities.Since2004,IDIhastrainedmorethan5,810healthcareprovidersfrom
27Africancountries.
•CardiovascularScreeningProject
This project involves the free CV medical screening of the general public and it
addresses the growing concern of cardiovascular diseases in Africa. The
programmes are held in pharmacies, religious organizations and corporate
establishments and in partnership with health care institutions. It covers health
parameters like blood pressure, glucose and cholesterol. Pfizer conducted free
screeningsforover5000personsin2010andthisyearhasscreenedmorepeople.
•GlaucomaScreenings
Glaucoma is the second leading cause of preventable blindness worldwide, not
becauseoflackofeffectivemethodsfordiagnosisandtreatment,butduetolimited
public awareness of the disease and its implications. It is asymptomatic in its early
stages, while the patient's vision suffers irreversible and cumulative damage. Visual
disturbances are noted by the patient at late stages on the way to blindness,
whereas timely diagnosis and therapy could have prevented this degradation. The
key to preventing the progression to vision loss is early detection hence Pfizer’s
decision to hold free screenings as part of its Corporate Social Responsibility (CSR)
activities. Working in partnership with the Federal Ministry of Health, the
Ophthalmological Society of Nigeria (OSN), Nigeria Optometric Association (NOA),
the Ayo Bello Foundation and several teaching hospitals, Pfizer has carried out
severalfreeglaucomascreeningspan-Nigeria.
Alkem labs Ltd was registered in
Kenya in 1999. The company is
amongst Top 10 (Ten) companies in
India with internationally recognized
brands such as CLAVAM, PAN 40 and
ENZOFLAM among others.
It has international approvals from
USFDA, UKMHRA, WHO – GMP to
mention a few.
Our key market includes USA,
Australia and European Union while
Kenya scores amongst the best
emerging markets.
ENZOFLAM PAN 40 ONDEM - MD
Bayer Pharmaceuticals
Bayer is a Life Science company with core
competencies in the areas of health care and
agriculture. With our innovative products, we are
contributing to finding solutions to some of the
major challenges of our time. Bayer is improving
people’s quality of life by preventing, alleviating and
treating diseases.
The Pharmaceuticals Division focuses on
prescription products, especially for cardiology and
women’s healthcare, and on specialty therapeutics in
the areas of oncology, hematology and
ophthalmology. The division also comprises the
Radiology Business Unit which markets
contrast-enhanced diagnostic imaging
equipment together with the necessary
contrast agents.
For more information, please visit
www.pharma.bayer.com

Surgilinks Ltd
“Your Excellent Link to Affordable Healthcare”
“Surgilinks”
Mombasa
Road,
P.O.
Box
14461-‐00800

Nairobi
-‐
Kenya.
Tel:
6651465/6/7/8,
Fax:
6651469

Email:
surgimail@surgilinksltd.com

Website:
http://www.surgilinksltd.com

Importers, Distributors, Wholesalers of
Pharmaceuticals Product

We
are
proud
to
be

Associated
with

M.P.Shah
Hospital

We
are
Agents
for;

Surgilinks Ltd
“Surgilinks”
Mombasa
Road,
P.O.
Box
14461-‐00800

Nairobi
-‐
Kenya.
Tel:
6651465/6/7/8,
Fax:
6651469

Email:

Website:


We
are
proud
to
be

Associated
with

M.P.Shah
Hospital

We
are
Agents
for;

Surgilinks Ltd
“Surgilinks”
Mombasa
Road,
P.O.
Box
14461-‐00800

Nairobi
-‐
Kenya.
Tel:
6651465/6/7/8,
Fax:
6651469

Email:

Website:


We
are
proud
to
be

Associated
with

M.P.Shah
Hospital

We
are
Agents
for;

OTHERSTORCHSTDsVIRALHEPATITIS
A R A Y O F H O P E
PHARMACEUTICALS LIMITED
The triple action antacid“Raft”
s u s p e n s i o n
For faster relief from
Heart-burn and Acid R
(Dextromethorphan, Phenylephrine & Cetirizine)
Controls dry cough safely
A R A Y O F H O P E
PHARMACEUTICALS LIMITED
HIGHRIDGE PHARMACEUTICALS LTD.
Amani Plaza, 3rd
Parklands Ave., P.O. Box 32982 00600, Nairobi.
Telephone No.3741875/3755505/3752847/Fax No. 3753038
E-mail: info@highpharm.co.ke; accounts@highpharm.co.ke
INTRODUCTION:
Highridge Pharmaceuticals Limited is a quality Pharmaceuticals, Laboratory Reagents, Rapid
Diagnostic Items, Medical Consumables, Surgical items and other Medical accessories importer,
exporter, distributor and wholesaler.
The business started in 1997 as a retail pharmacy. Over the years, the company has subsequently
grown and extended its operational services to larger healthcare institutions, hence developing a
fully-fledged Pharmacy & Poisons Board Kenya (PPB) certified wholesale division which
commenced in November 2002. Ever since, we have endeavoured to provide our reputable
clientele with the highest quality healthcare products and services in the Country today. The Chief
Managers of our Company have a collective work experience of over 30 years in the
Pharmaceutical, Laboratory, Surgical and Diagnostic supplies business throughout East and Central
Africa.
Highridge Pharmaceuticals Ltd., therefore believes that it is a well-equipped and qualified
establishment, having supplied and delivered quality healthcare products to all leading major
institutions countrywide, including the Aga Khan University Hospitals (East Africa), Gertrudes
Children’s Hospital, Kenyatta National Hospital (KNH), Kenya Medical Supplies Agency
(KEMSA), Mission for Essential drugs and supplies (MEDS), The Kenya Red Cross, The Walter
Reed Project, The Karen Hospital and the Nairobi Hospital to name a few. Hence, we feel that we
are able to perform any contracts successfully & satisfactorily according to the client’s specific
needs and requirements.
Highridge Pharmaceuticals Ltd aims to become one of the most prominent and reputable
pharmaceutical & healthcare product distributor and service provider in the East African region.
The Company’s policy of holding adequate stocks of all items on its expansive price list has
generated a broader and more satisfied clientele base throughout the region. The management of
the Company is therefore committed to fielding a proactive approach in meeting its client’s needs
in order to maximize customer satisfaction.
We are the first company to have brought in Niche products including the lifesaving Lipholyn
(Liposomal Amphotericin B) and Qurion (silver ionic solution for difficult to treat wounds), both
of which were the first of its kind in the market. In addition to this, the company has also
introduced Enzymatic Cleaners, Rust removers and Lubricants from USA to control hospital
infection and maintain instruments and scopes to increase longevity and reduce repairs and
replacement costs.
Hence from its humble beginnings, the business today has grown in stature attracting reputable
healthcare agencies, as well as creating new innovative avenues of business throughout the region.

WITH BEST
COMPLIMENTS TO
THE COMMITTEE
OF THE 5TH
INFECTIOUS DISEASE
SYMPOSIUM 2016
For more information, please contact: CIPLA KENYA Ltd. c/o Surgipharm Ltd., Nairobi, Kenya. Tel: 020 3749304
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
NOTES
M. P. SHAH HOSPITAL

__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
NOTES

Symposium booklet 2016

Recommended

Recommended

More Related Content

What's hot

What's hot (18)

Viewers also liked

Viewers also liked (9)

Similar to Symposium booklet 2016

Similar to Symposium booklet 2016 (20)

Recently uploaded

Recently uploaded (20)

Symposium booklet 2016